UNSPSC 51284800: Combination antibacterials

This classification denotes combination drugs that reduce the growth or reproduction of bacteria. Typical combination antibacterial constituents are benzalkonium, benzethonium chloride, camphor, chlorhexidine gluconate, ichthammol, and iodine.

UNSPSC 51284800 Combination antibacterials is a Class code that encompasses pharmaceuticals and medical supplies state and local governments procure for emergency response, community health programs, and institutional pharmacy benefit operations. Recent solicitations show state and local bodies buying naloxone and drug deactivation systems, emergency medical supplies for fire rescue divisions, and generic pharmaceuticals and over-the-counter products through cooperative purchasing agreements. The work spans acquisition of finished pharmaceutical products, emergency medical consumables, and supply chain coordination through authorized wholesalers and direct-to-manufacturer channels.

Issuing bodies include county health departments, municipal fire departments, state health and human services agencies, and cooperative purchasing organizations serving multiple jurisdictions. Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted activity under or adjacent to this code in the past six months. Activity concentrates in Florida and Minnesota, with multi-state cooperative purchasing extending into Oregon and other participating jurisdictions. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (posted June 30, 2026, response due July 26, 2023), the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000.00 (posted March 25, 2026, response due March 13, 2026, designated as sheltered for certified Small Local Business Enterprises with a 5 percent bid discount), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (posted January 20, 2026, response due March 26, 2026). The Texas HHS Commission issued an exploratory RFI in March 2026 regarding direct-to-manufacturer prescription programs, signaling potential future procurement activity in therapeutic pharmacy initiatives.